Recruiting Rheumatoid Arthritis Studies in Sayre
About Rheumatoid Arthritis Clinical Trials in Sayre
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.
There are currently 1 rheumatoid arthritis clinical trials recruiting participants in Sayre, PA. These studies are seeking a combined 994 participants. Research is being sponsored by Jason Sperry. Clinical trial participation is free and participants receive study-related medical care at no cost.
Rheumatoid Arthritis Clinical Trials in Sayre — FAQ
Are there rheumatoid arthritis clinical trials in Sayre?
Yes, there are 1 rheumatoid arthritis clinical trials currently recruiting in Sayre, PA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Sayre?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sayre research site will contact you about next steps.
Are clinical trials in Sayre free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sayre studies also compensate for your time and travel.
What rheumatoid arthritis treatments are being tested?
The 1 active trials in Sayre are testing new therapies including novel drugs, biologics, and treatment approaches for rheumatoid arthritis.
Data updated March 2, 2026 from ClinicalTrials.gov